1118 Participants Needed

Evaluation of Efficacy and Safety of Suzetrigine for Acute Pain After an Abdominoplasty

Recruiting at 11 trial locations
MI
Overseen ByMedical Information
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: Vertex Pharmaceuticals Incorporated
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial is testing VX-548, a new medication, to see if it can help reduce pain in patients who have had abdominoplasty surgery. VX-548 likely works by blocking pain signals in the body.

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.

Are You a Good Fit for This Trial?

Inclusion Criteria

Before Surgery: Participant scheduled to undergo a standard ('full') abdominoplasty procedure
After Surgery: Participant is lucid and able to follow commands and able to swallow oral medications
After Surgery: All analgesic guidelines were followed during and after the abdominoplasty
See 1 more

Exclusion Criteria

Before Surgery: Prior history of abdominoplasty
After Surgery: Participant had a non standard abdominoplasty, collateral procedures during the abdominoplasty or any surgical complications during the abdominoplasty
Before Surgery: History of Intra-abdominal and/or pelvic surgery that resulted into complications
See 3 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive VX-548, HB/APAP, or placebo for acute pain management after abdominoplasty

6 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • HB/APAP
  • Placebo (matched to HB/APAP)
  • Placebo (matched to VX-548)
  • VX-548
How Is the Trial Designed?
3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Suzetrigine (SUZ)Experimental Treatment2 Interventions
Participants received SUZ \[100 mg as first dose, followed by 50 mg every 12 hours (q12h)\] for 48 hours.
Group II: Hydrocodone bitartrate/acetaminophen (HB/APAP)Active Control2 Interventions
Participants received HB 5 milligrams (mg)/ APAP 325 mg every 6 hours (q6h) for 48 hours.
Group III: PlaceboPlacebo Group2 Interventions
Participants received placebo matched to Suzetrigine (SUZ) and Hydrocodone bitartrate/acetaminophen (HB/APAP) for 48 hours.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Vertex Pharmaceuticals Incorporated

Lead Sponsor

Trials
267
Recruited
36,100+
Dr. David Altshuler profile image

Dr. David Altshuler

Vertex Pharmaceuticals Incorporated

Chief Medical Officer since 2020

MD, PhD

Dr. Reshma Kewalramani profile image

Dr. Reshma Kewalramani

Vertex Pharmaceuticals Incorporated

Chief Executive Officer since 2020

MD, trained in internal medicine and nephrology

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security